Pages that link to "Q42085981"
Jump to navigation
Jump to search
The following pages link to Increased frequency of ICOS+ CD4 T cells as a pharmacodynamic biomarker for anti-CTLA-4 therapy (Q42085981):
Displaying 50 items.
- Novel technologies and emerging biomarkers for personalized cancer immunotherapy (Q26770780) (← links)
- Predictive factors for immunotherapy in melanoma (Q26778765) (← links)
- Biomarkers for glioma immunotherapy: the next generation (Q26825496) (← links)
- Immune Checkpoint Blockade in Cancer Therapy (Q26830509) (← links)
- The role of immune checkpoint inhibition in the treatment of ovarian cancer (Q28077924) (← links)
- The future of immune checkpoint therapy (Q28259862) (← links)
- Mechanisms of action of therapeutic antibodies for cancer (Q28385366) (← links)
- Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial (Q30407940) (← links)
- Ipilimumab treatment decreases monocytic MDSCs and increases CD8 effector memory T cells in long-term survivors with advanced melanoma (Q33591598) (← links)
- Tumor immunology and cancer immunotherapy: summary of the 2013 SITC primer (Q33689478) (← links)
- ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells (Q34047847) (← links)
- Combination cancer immunotherapy and new immunomodulatory targets (Q34487698) (← links)
- The coinhibitory receptor CTLA-4 controls B cell responses by modulating T follicular helper, T follicular regulatory, and T regulatory cells. (Q35021671) (← links)
- Peripheral T cell receptor diversity is associated with clinical outcomes following ipilimumab treatment in metastatic melanoma (Q35748121) (← links)
- Immunological correlates of treatment and response in stage IV malignant melanoma patients treated with Ipilimumab (Q36821143) (← links)
- Intellectual property issues of immune checkpoint inhibitors (Q37138243) (← links)
- Ipilimumab reshapes T cell memory subsets in melanoma patients with clinical response. (Q37222127) (← links)
- Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities (Q37369239) (← links)
- A Pilot Study of Preoperative Single-Dose Ipilimumab and/or Cryoablation in Women with Early-Stage Breast Cancer with Comprehensive Immune Profiling (Q37509479) (← links)
- CD4 T cells require ICOS-mediated PI3K signaling to increase T-Bet expression in the setting of anti-CTLA-4 therapy (Q37732951) (← links)
- Manipulation of regulatory T cells and antigen-specific cytotoxic T lymphocyte-based tumour immunotherapy (Q38253084) (← links)
- Ipilimumab in the treatment of advanced melanoma - a clinical update (Q38253823) (← links)
- Immune checkpoint combinations from mouse to man. (Q38306150) (← links)
- Monitoring immune responses in the tumor microenvironment (Q38380080) (← links)
- Immunotherapy in Cancer: A Combat between Tumors and the Immune System; You Win Some, You Lose Some (Q38413904) (← links)
- Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential (Q38414485) (← links)
- Pilot and Feasibility Trial Evaluating Immuno-Gene Therapy of Malignant Mesothelioma Using Intrapleural Delivery of Adenovirus-IFNα Combined with Chemotherapy (Q38416306) (← links)
- Neoadjuvant therapy in muscle-invasive bladder cancer: a model for rational accelerated drug development (Q38424928) (← links)
- Challenges faced when identifying patients for combination immunotherapy (Q38638046) (← links)
- Metabolomics combined with pattern recognition and bioinformatics analysis methods for the development of pharmacodynamic biomarkers on liver fibrosis. (Q38696814) (← links)
- VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer (Q38710357) (← links)
- Emerging Tissue and Blood-Based Biomarkers that may Predict Response to Immune Checkpoint Inhibition. (Q38753031) (← links)
- Programmed cell death-1 blockade enhances response to stereotactic radiation in an orthotopic murine model of hepatocellular carcinoma. (Q38753059) (← links)
- Immunogenomics: using genomics to personalize cancer immunotherapy. (Q38772744) (← links)
- Immune Checkpoint Therapy and the Search for Predictive Biomarkers (Q38816815) (← links)
- Combinatorial approach to cancer immunotherapy: strength in numbers (Q38852256) (← links)
- Immunoregulatory functions of VISTA. (Q38930123) (← links)
- Gene-expression profiling to predict responsiveness to immunotherapy (Q39005203) (← links)
- Immunotherapy of cancers comes of age. (Q40099075) (← links)
- Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with Ipilimumab (Q40758666) (← links)
- Synthetic RORγ agonists regulate multiple pathways to enhance antitumor immunity (Q40806737) (← links)
- Hallmarks of response to immune checkpoint blockade (Q41078811) (← links)
- The inducible costimulator augments Tc17 cell responses to self and tumor tissue. (Q41551980) (← links)
- Predictors of responses to immune checkpoint blockade in advanced melanoma (Q41701241) (← links)
- Genomic landscape associated with potential response to anti-CTLA-4 treatment in cancers. (Q42380545) (← links)
- Immune Activation in Early-Stage Non-Small Cell Lung Cancer Patients Receiving Neoadjuvant Chemotherapy Plus Ipilimumab. (Q45959320) (← links)
- Tumor immunology and cancer immunotherapy: summary of the 2014 SITC primer. (Q46090703) (← links)
- Immune Toxicities Elicted by CTLA-4 Blockade in Cancer Patients Are Associated with Early Diversification of the T-cell Repertoire (Q46177852) (← links)
- Ipilimumab plus Lenalidomide after Allogeneic and Autologous Stem Cell Transplantation for Patients with Lymphoid Malignancies (Q47287683) (← links)
- The need for immune biomarkers for treatment prognosis and response in genitourinary malignancies (Q49545290) (← links)